Business Wire

TX-MAVENIR

11.2.2020 14:02:08 CET | Business Wire | Press release

Share
Mavenir and MUGLER Collaborate to Deliver Mavenir End-to-End 5G Private Networks in Germany

Mavenir, the industry's only end-to-end cloud-native 4G/5G network software provider for CSPs, has announced collaboration and joint go-to-market with MUGLER, a leading and well-established neutral system integrator for telco networks in Germany, to deliver Mavenir’s end-to-end 5G solutions including 5G vRAN, 5G Core & Digital Enablement Platform to the German Enterprise & Industry Market, enabled by the German Government’s Private Networks initiative and the allocation of spectrum for private enterprise and industry use.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005394/en/

Mavenir will offer its full portfolio of 4G and 5G solutions for the German Private Networks market to address the needs of Enterprises, Industries and Service Providers. Mugler will act as go to market partner for Mavenir as well as a value-added reseller including systems integration and local operation and support. In addition, Mugler has secured a private networks license from BNetzA (the German frequency regulator) and will deploy an end-to-end 5G system on its own campus at Oberlungwitz (Saxony, Germany). This network will be used for advanced enterprise use cases such as AGVs for logistics, AR/VR, IoT, Video, Broadcast and Secure Communications for Mugler’s enterprise needs, as well as a showcase and testbed for end customers.

Jointly, the companies will address the growing business opportunity for private networks for the Industry, Media, Health, Public Authorities and Service Provider segments and customers.

A Comprehensive Private Networks Solution for Enterprises and Industries

The German Government’s private networks initiative has allocated spectrum in the 3.7-3.8 GHz band for enterprises and industries to build their own mobile networks in environments such as campuses, venues, offices, factories and ports etc.

Mavenir’s OpenRAN vRAN encompasses 4G and 5G radio access, and the disaggregated RAN approach extends virtualization to the edge of the network and provides strategic differentiation by enabling multisource Remote Radio Units (RRUs) to interwork with the virtualized, containerized, Cloud Base Band software over ethernet Fronthaul (FH), using the O-RAN open interface overcoming the traditional constraints of the proprietary walled garden specifications used by the other traditional equipment vendors.

Mavenir’s 5G Core solution , based on cloud-native principles, can be retrofitted on EPCs and encompasses all the major 5G core elements, and these functions are implemented as micro-services in containers. The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobile Core’ solution that supports both 4G and 5G subscribers. In addition, the Mavenir 5G Core supports all Standalone (SA) and Non-Standalone (NSA) options.

Mavenir’s Digital Enablement platform allows Private Network operators to create a seamless way of abstracting out the complexity of the underlying network, and create a digital app store for enterprise and industry applications – thereby empowering an ecosystem of developers, service providers, technology companies, enterprises and industries to create applications to power digitalization with 5G.

This end-to-end 5G system, based on cloud-first and open architecture principles, is highly suited to address both mass scale private enterprise use cases as well as bespoke high-end use cases for advanced industries. The solution can be delivered as on-prem “network-in-a-box”, cloud-based “Network-as-a-Service” or Hybrid models.

With Mugler’s advanced services those networks can be deployed as turn-key solutions anywhere in Germany and beyond. Furthermore, Mugler’s Telco mplete® - Process covers the whole lifecycle of telco networks and infrastructure with all managed services, including end to end network design and planning, systems integration, deployment, support, maintenance, repair and field service 365/24/7.

Quotes

“As 5G use cases are emerging, together with Mugler, we are bringing our 4G/5G virtualized portfolio of solutions to the German market for quick and easy deployments,” said Aniruddho Basu, Mavenir’s SVP/GM of Emerging Business. “Mavenir’s OpenRAN vRAN and Converged Mobile Core solutions provide a cost-efficient approach to addressing the rising need for private networks for enterprises, industries and service providers.”

“Private networks will revolutionize a lot of industries. They will have an enormous leverage for digitization,” said Fabian Berger, Mugler’s Director Local Networks. “To deploy and operate those networks flexibly and cost effectively, OpenRAN and virtualized networks are up-and-coming. We see Mavenir as a strong partner to be able to quickly develop and deploy customized private networks for different industries and customers.”

About Mavenir

Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve webscale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at www.mavenir.com

About Mugler

Mugler is a medium-sized company based and mainly active in Germany. Since the foundation of our company in 1990, we have become a well-established and leading service provider and neutral system integrator for telecommunication networks and infrastructure in Germany. Today 320 employees implement our slogan “from idea to network” with our full-service Telco mplete®-Process, covering the complete lifecycle of all kinds of telecommunication infrastructure including network design and planning, systems integration, deployment, maintenance, operation and support.

With this and our long lasting know-how we are able to provide and maintain sustainable networks to all kinds of customers, from the large German CSPs (mobile and fixed) to public authorities, as well as large and smaller companies.

Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.

Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye